ReviewInternational journal of molecular sciences2024
First Trimester Placental Biomarkers for Pregnancy Outcomes.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Identification of risk factors and development of a predictive model for foetal growth restriction: a retrospective case-control study.Annals of medicine · 2026Article
- Gene regulation at the early human maternal-fetal interface.Nature reviews. Genetics · 2026Review
- Prognostic nutritional index as a predictor of fetal growth restriction and adverse perinatal outcomes.Irish journal of medical science · 2026Article
- Extracellular vesicles in pregnancy-related disorders: from mechanisms to clinical implications.Science China. Life sciences · 2026Review
- Reappraisal of adverse obstetric outcomes independently associated with contemporary fertility treatment practices: a US prospective cohort study.American journal of obstetrics and gynecology · 2026Article
- The placental maturation inflection point: an integrative biological framework for understanding early-onset versus late-onset preeclampsia.Frontiers in endocrinology · 2026Review
- Obesity concurrent with gestational diabetes mellitus dysregulates mitochondria-endoplasmic reticulum contacts in human placenta.Scientific reports · 2025Article
- Navigating Cellular Stress: Endoplasmic Reticulum Stress and the Unfolded Protein Response in the Molecular Pathogenesis of Preeclampsia.Cell biochemistry and biophysics · 2025Review
- Gene Expression Profile of Placenta and Adipose Tissue in Women with Gestational Diabetes Mellitus.International journal of molecular sciences · 2025Article
- Is It Worth Assessing the Prevalence of Sarcopenia in Pregnant Women? Should Any Impact on Pregnancy Outcomes Be Expected?Nutrients · 2025Review
- Association of First-Trimester Maternal Biomarkers with Preeclampsia and Related Maternal and Fetal Severe Adverse Events.International journal of molecular sciences · 2025Article
- Role of Gestosis Scoring and Pentamarker in Prediction of Pregnancy-Induced Hypertension (PIH) in Primigravida.Cureus · 2025Article
- The Role of Oxidative Stress-Induced Senescence in the Pathogenesis of Preeclampsia.Antioxidants (Basel, Switzerland) · 2025Review
- Integrated analysis of DNA methylation and transcriptome profiles to identify oxidative stress-related placenta-specific molecules for preeclampsia.The journal of obstetrics and gynaecology research · 2025Article
- The Relationship Between Thrombophilia and Modifications in First-Trimester Prenatal Screening Markers.Medicina (Kaunas, Lithuania) · 2025Observational
- Bioinformatic Analysis of Apoptosis-Related Genes in Preeclampsia Using Public Transcriptomic and Single-Cell RNA Sequencing Datasets.Journal of inflammation research · 2025Article
- sFlt-1/PlGF and beyond: angiolymphatic-associated signatures and emerging biomarkers in placental pathology.Vascular biology (Bristol, England) · 2025Review
- Preeclampsia and eclampsia: Enhanced detection and treatment for morbidity reduction.Best practice & research. Clinical anaesthesiology · 2024Review
- Editorial: Gestational diabetes: where are we and where are we going?Frontiers in clinical diabetes and healthcare · 2024Article
- Unveiling the Network regulatory mechanism of ncRNAs on the Ferroptosis Pathway: Implications for Preeclampsia.International journal of women's health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The placenta plays a key role in several adverse obstetrical outcomes, such as preeclampsia, intrauterine growth restriction and gestational diabetes mellitus. The early identification of at-risk pregnancies could significantly improve the management, therapy and prognosis of these pregnancies, especially if these at-risk pregnancies are identified in the first trimester. The aim of this review was to summarize the possible biomarkers that can be used to diagnose early placental dysfunction and, consequently, at-risk pregnancies. We divided the biomarkers into proteins and non-proteins. Among the protein biomarkers, some are already used in clinical practice, such as the sFLT1/PLGF ratio or PAPP-A; others are not yet validated, such as HTRA1, Gal-3 and CD93. In the literature, many studies analyzed the role of several protein biomarkers, but their results are contrasting. On the other hand, some non-protein biomarkers, such as miR-125b, miR-518b and miR-628-3p, seem to be linked to an increased risk of complicated pregnancy. Thus, a first trimester heterogeneous biomarkers panel containing protein and non-protein biomarkers may be more appropriate to identify and discriminate several complications that can affect pregnancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.